ABAFUNGIN

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H22N4OS
Molecular Weight	378.491
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC=C(OC2=CC=CC=C2C3=CSC(N=C4NCCCN4)=N3)C(C)=C1

InChI

InChIKey=TYBHXIFFPVFXQW-UHFFFAOYSA-N

InChI=1S/C21H22N4OS/c1-14-8-9-18(15(2)12-14)26-19-7-4-3-6-16(19)17-13-27-21(24-17)25-20-22-10-5-11-23-20/h3-4,6-9,12-13H,5,10-11H2,1-2H3,(H2,22,23,24,25)

HIDE SMILES / InChI

Molecular Formula	C21H22N4OS
Molecular Weight	378.491
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18587237 | https://web.archive.org/web/20070927102715/http://www.yorkpharma.com/media/YRK-Update_Abasol_061002-FN.pdf | https://www.ncbi.nlm.nih.gov/pubmed/18587237 | https://www.google.com/patents/EP2331086A2

Abafungin is a broad-spectrum antifungal agent with a novel mechanism of action for the treatment of dermatomycoses and onychomycosis. Abafungin acts through inhibition of transmethylation at the C-24 position of the sterol side chain, catalyzed by the enzyme sterol-C-24-methyltransferase. Abasol is a topical cream formulation of abafungin seeking approval in 2008 in European markets.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
sterol 24-C-methyltransferase activity 1 Target ID: GO:0003838 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18587237	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Dermatomycosis 20 Sources: https://www.google.com/patents/WO2009053741A2 https://www.google.com/patents/US20110059985 https://www.ncbi.nlm.nih.gov/pubmed/18587237	Primary		Phase III 656	Unknown Approved Use Unknown
Onychomycosis 18 Sources: https://www.google.com/patents/WO2009053741A2 https://www.google.com/patents/US20110059985 https://www.ncbi.nlm.nih.gov/pubmed/18587237	Primary		Phase III 656	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Gateways to clinical trials.	2010 Jan-Feb	20383346

Patents

Sample Use Guides

In Vivo Use Guide

In formulated creams and gels, abafungin 1% to 30%, applied once daily for 1 to 3 months

Route of Administration: Topical

In Vitro Use Guide

MICs were determined using Kimmig’s and T3 media for dermatophytes, and YNB glucose and T3 medium for yeast-like fungi in physiological saline or in demineralized water. MIC's between 0.06 ug/mL and 1.0 ug/mL depending on species. The non-growing dermatophytes and yeastlike fungi were killed with Abafungin concentrations

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:18:30 GMT 2023` Edited by `admin` on `Fri Dec 15 16:18:30 GMT 2023`
Record UNII	11DI31LWXF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ABAFUNGIN

Official Name

English

BAY-W-6341

Code

English

BAY W 6341

Code

English

abafungin [INN]

Common Name

English

HEXAHYDRO-2-((4-(O-(2,4-XYLYLOXY)PHENYL)-2-THIAZOLYL)IMINO)PYRIMIDINE

Common Name

English

BAY-W-6341-

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C514